Key Highlights

  • MDGL shares rose 12.15% pre-market to $483.53 after third-quarter results.
  • Rezdiffra net sales were $431.3 million, up 50% year over year.
  • Net income was $55.4 million, the company's first profitable quarter.

Madrigal Pharmaceuticals (NASDAQ:MDGL) shares rose 12.15% to $483.53 in pre-market today, up $52.38 from the prior close of $431.16. The company reported third-quarter Rezdiffra net sales of $431.3 million, up 50% from $287.3 million and compared with a consensus of roughly $404 million. Net Income was $55.4 million, or $1.83 per diluted share, compared with a net loss of $114.2 million, or $4.01 per share, and an expected loss.

Madrigal is a West Conshohocken, Pennsylvania-based commercial-stage biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis, or MASH. Rezdiffra (resmetirom) is a once-daily, oral, liver-directed THR-beta agonist and the first medication approved by the FDA and the European Commission for MASH with moderate to advanced fibrosis. The company has 915 employees.

Rezdiffra Reaches Blockbuster Status

Year-to-date Rezdiffra net sales reached $1.1 billion, less than three years after launch. More than 55,850 patients were on Rezdiffra at September 30, 2026, nearly double the third quarter of 2025. The U.S. F2-F3 MASH market grew to more than 530,000 addressable patients through June 30, 2026, and is on track for growth of more than 30% by year end.

Operating expenses were $375.3 million, compared with $401.2 million. Cost of sales was $37.8 million, compared with $18.1 million, driven by higher royalties payable to Roche. R&D expenses were $71.8 million, compared with $174.0 million, which included a one-time upfront Business development expense of $117.3 million in the prior-year period. SG&A expenses were $265.7 million, compared with $209.1 million, reflecting an endocrinology field force expansion and a direct-to-consumer campaign. Cash, cash equivalents, restricted cash and marketable securities were $961.8 million at September 30, compared with $988.6 million at December 31, 2025.

New Cirrhosis Trial and a Heavy Presence at the Liver Meeting

Madrigal plans to start MAESTRO-CSPH, a second Phase 3 event-driven outcomes trial, enrolling more than 2,000 patients with compensated MASH cirrhosis, or F4c, in the first half of 2027, subject to regulatory discussions. Data from the ongoing MAESTRO-NASH OUTCOMES trial are expected in late 2027.

At the AASLD Liver Meeting in Denver from November 5 to 9, Madrigal has 18 accepted abstracts, including 13 based on real-world evidence, the largest of which covers nearly 12,000 patients. A Journal of Hepatology publication showed consistent efficacy across common MASH genetic variants including PNPLA3 and HSD17B13. Dr. John Reed of Johnson & Johnson joined the board of directors. The consensus analyst target is near $685, and the 52-week range is $399.00 to $615.00.

Liver Meeting Presentations and F4c Outcomes Data Are the Next Markers

Madrigal reported its first profitable quarter, higher Rezdiffra sales and a growing patient base. The next items to follow are the conference call today, the November 5 to 9 AASLD Liver Meeting, the first-half 2027 start of MAESTRO-CSPH and MAESTRO-NASH OUTCOMES data in late 2027.